Lindsay Colin R, MacPherson Iain Rj, Cassidy Jim
Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK.
Future Oncol. 2009 May;5(4):421-32. doi: 10.2217/fon.09.18.
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis. It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-molecule inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets. This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy.
血管生成是肿瘤形成新血管以促进生长和转移的过程，是肿瘤发生中的关键事件。它受血管内皮生长因子（VEGF）系统的严格调控。西地尼布（AZD2171，Recentin；阿斯利康公司，英国伦敦）是一种新型强效小分子VEGF信号抑制剂，对三种VEGF受体以及其他靶点均有活性。本文全面且最新地概述了所有相关的临床前和临床研究，详细介绍了这种有前景的新疗法。
